Business Informer
Monday, March 27, 2023
No Result
View All Result
  • Home
  • Business
  • Stocks
  • Economy
  • Markets
  • Startups
  • Invest
  • Crypto
  • Forex
  • PF
  • Real Estate
  • Fintech
  • Analysis
  • Videos
  • Home
  • Business
  • Stocks
  • Economy
  • Markets
  • Startups
  • Invest
  • Crypto
  • Forex
  • PF
  • Real Estate
  • Fintech
  • Analysis
  • Videos
Business Informer
No Result
View All Result

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 By Investing.com

March 16, 2023
in Markets
Reading Time: 2 mins read
0 0
A A
0
Home Markets
Share on FacebookShare on Twitter



Leap Therapeutics (LPTX) Gives Replace on BeiGene (BGNE) Choice Settlement for DKN-01

Leap Therapeutics, Inc. (Nasdaq:NASDAQ:), a biotechnology firm targeted on growing focused and immuno-oncology therapeutics, in the present day introduced that BeiGene (NASDAQ:)’s possibility underneath the Unique Choice and License Settlement between Leap and BeiGene granting rights in sure Asian territories to DKN-01, Leap’s anti-DKK1 monoclonal antibody, has expired in accordance with the phrases of the settlement. Leap and BeiGene will proceed to collaborate on the continued Half C of the DisTinGuish trial, a randomized managed trial of DKN-01 together with BeiGene’s anti-PD-1 antibody, tislelizumab, and chemotherapy in first-line gastric most cancers sufferers, as a medical collaboration with BeiGene supplying tislelizumab. Enrollment within the 160-patient examine is anticipated to be accomplished in late 2023.

“We look ahead to persevering with to collaborate with BeiGene to execute on our first randomized managed trial for DKN-01 in first-line gastric most cancers sufferers,” stated Douglas E. Onsi, President and Chief Government Officer of Leap. “With international rights to DKN-01 and a money runway that was enhanced into mid-2025 by our latest acquisition of Flame Biosciences, we’ll look to determine a brand new strategic associate as we generate new medical information from our ongoing research in first-line gastric most cancers sufferers, second-line colorectal most cancers sufferers, and an investigator-sponsored examine in endometrial most cancers sufferers. We may even proceed the event of the newly-acquired Claudin18.2 applications as a part of our concentrate on biomarker-targeted antibody therapies for most cancers sufferers, notably these with GI cancers.”



Source link

Tags: AgreementBeiGeneDKN01Investing.comLeapOptionTherapeuticsUpdate
Previous Post

Economic calendar in Asia is nearly empty – Friday, 17 March 2023

Next Post

U.S. Judge Criticizes SEC Over Voyager Acquisition Deal

Related Posts

Did Wall Street HELP the Housing Market?
Markets

Did Wall Street HELP the Housing Market?

by Business Informer
March 27, 2023
You Will Be Shocked By How Much Money Is Being Pulled Out Of U.S. Banks, And Now The Biggest Bank In Germany Is In Trouble – Investment Watch
Markets

You Will Be Shocked By How Much Money Is Being Pulled Out Of U.S. Banks, And Now The Biggest Bank In Germany Is In Trouble – Investment Watch

by Business Informer
March 27, 2023
Ethereum is at risk of losing its dominant status in DeFi — here’s why (ETH-USD)
Markets

Ethereum is at risk of losing its dominant status in DeFi — here’s why (ETH-USD)

by Business Informer
March 26, 2023
Kyiv calls for UN Security Council session over Putin’s nuclear plans By Reuters
Markets

Kyiv calls for UN Security Council session over Putin’s nuclear plans By Reuters

by Business Informer
March 26, 2023
Deposit drain from small banks into JPM, WFC, C slowed
Markets

Deposit drain from small banks into JPM, WFC, C slowed

by Business Informer
March 26, 2023
Next Post
U.S. Judge Criticizes SEC Over Voyager Acquisition Deal

U.S. Judge Criticizes SEC Over Voyager Acquisition Deal

Kentucky university settles over wrestler’s heat stroke death

Kentucky university settles over wrestler's heat stroke death

One year after the first rate hike, the Fed stands at policy crossroads

One year after the first rate hike, the Fed stands at policy crossroads

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE TO OUR NEWSLETTER

* indicates required

Business Informer

Follow the latest news on Business Informer. Stay updated on business, markets, economy & financial breaking news on a daily basis.

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Fintech
  • Forex
  • Investing
  • Market Analysis
  • Markets
  • Personal Finance
  • Real Estate
  • Startups
  • Stock Market
  • Videos

LATEST UPDATES

  • iShares Mortgage Real Estate Capped ETF: Real Estate Facing A Deep Freeze (BATS:REM)
  • March 2023 Miscellany | Stock Gumshoe
  • US Dollar (DXY) Subdued, Banks Gain, US Treasury Yields Move Higher
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2023 Business Informer.
Business Informer Business Informer

No Result
View All Result
  • Home
  • Business
  • Stocks
  • Economy
  • Markets
  • Startups
  • Invest
  • Crypto
  • Forex
  • PF
  • Real Estate
  • Fintech
  • Analysis
  • Videos

Copyright © 2023 Business Informer.
Business Informer Business Informer

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In